Literature DB >> 21505156

Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care.

Adam J Rose1, Elaine M Hylek, Dan R Berlowitz, Arlene S Ash, Joel I Reisman, Al Ozonoff.   

Abstract

BACKGROUND: Improved control of oral anticoagulation reduces adverse events. A program of quality measurement is needed for oral anticoagulation. The interval until the next test after an out-of-range International Normalized Ratio (INR) value (the "follow-up interval") could serve as a process of care measure. METHODS AND
RESULTS: We studied 104 451 patients cared for by 100 anticoagulation clinics in the Veterans Health Administration (VA). For each site, we computed the average follow-up interval after low (≤1.5) or high (≥4.0) INR. Our outcome was each site's average anticoagulation control, measured by percent time in therapeutic range (TTR); 59 837 patients (57%) contributed to the low INR analysis, 37 697 (36%) contributed to the high INR analysis, and all patients contributed to the dependent variable (mean site TTR). After a low INR, site mean follow-up interval ranged from 10 to 24 days. Longer follow-up intervals were associated with worse site-level control (1.04% lower for each additional day, P<0.001). After a high INR, site mean follow-up interval ranged from 6 to 18 days, with longer follow-up intervals associated with worse site-level control (1.12% lower for each additional day, P<0.001). These relationships were somewhat attenuated but still highly statistically significant when the proportion of INR values in-range was used as the dependent variable rather than TTR.
CONCLUSIONS: Prompt repeat testing after out-of-range INR values is associated with better anticoagulation control at the site level and could be an important part of a quality improvement effort for oral anticoagulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21505156     DOI: 10.1161/CIRCOUTCOMES.110.960096

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  14 in total

1.  Effectiveness and safety of therapy with vitamin K antagonists in Italian patients aged 80 years or older: a multicentre retrospective study comparing the Zeus algorithm with the PARMA algorithm or manual therapy.

Authors:  Arturo Cafolla; Luigia Manisco; Erminia Baldacci; Alessandro Porcu; Melissa Campanelli; Maria Concetta Cursano; Enza Rossi; Francesco Dragoni; Roberto Foà
Journal:  Drugs Aging       Date:  2015-03       Impact factor: 3.923

Review 2.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Anne Holbrook; Sam Schulman; Daniel M Witt; Per Olav Vandvik; Jason Fish; Michael J Kovacs; Peter J Svensson; David L Veenstra; Mark Crowther; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  A Practical Guide to Using the Positive Deviance Method in Health Services Research.

Authors:  Adam J Rose; Megan B McCullough
Journal:  Health Serv Res       Date:  2016-06-28       Impact factor: 3.402

4.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Authors:  Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt
Journal:  Blood Adv       Date:  2018-11-27

Review 5.  Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement.

Authors:  Elaine M Hylek
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

6.  The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial.

Authors:  David B Matchar; Sean R Love; Alan K Jacobson; Robert Edson; Lauren Uyeda; Ciaran S Phibbs; Rowena J Dolor
Journal:  J Thromb Thrombolysis       Date:  2015-07       Impact factor: 2.300

7.  Development and Implementation of National Time in Therapeutic Range Reports and Establishing Quality Standards Within Veterans Health Administration.

Authors:  Michael H Tran; Heather L Ourth; Anthony P Morreale
Journal:  J Gen Intern Med       Date:  2021-01-19       Impact factor: 5.128

8.  Geographic variations in the quality of oral anticoagulation with vitamin k antagonists in the era of new anticoagulants.

Authors:  Laurent Fauchier; Sophie Taillandier
Journal:  J Am Heart Assoc       Date:  2013-02-19       Impact factor: 5.501

9.  Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.

Authors:  Daniel E Singer; Anne S Hellkamp; Jonathan P Piccini; Kenneth W Mahaffey; Yuliya Lokhnygina; Guohua Pan; Jonathan L Halperin; Richard C Becker; Günter Breithardt; Graeme J Hankey; Werner Hacke; Christopher C Nessel; Manesh R Patel; Robert M Califf; Keith A A Fox
Journal:  J Am Heart Assoc       Date:  2013-02-19       Impact factor: 5.501

10.  Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation.

Authors:  Alberto Tosetto; Cesare Manotti; Francesco Marongiu
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.